A researcher has uncovered the M.O. of a mysterious molecule called SPRIGHTLY that acts as a hub for cancer-related genes in the nucleus. The study identified ‘major’ RNA binding partners — genes already implicated in a variety of cancers. In a mouse model of melanoma, tumors with reduced SPRIGHTLY grew more slowly, indicating use as a therapeutic target or biomarker.